Cargando…

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease

Tumor necrosis factor-α (TNF-α)-inhibiting agents are a standard therapy for moderate-to-severe inflammatory bowel disease (IBD). IgA nephropathy in the setting of prolonged exposure to TNF-α inhibitors is a rare, clinically significant adverse event often overlooked by gastroenterologists but well...

Descripción completa

Detalles Bibliográficos
Autores principales: Strobel, Thomas, Ahmed, Waseem, De la Sancha, Carlo, Bohm, Matthew, Fischer, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526714/
https://www.ncbi.nlm.nih.gov/pubmed/33062795
http://dx.doi.org/10.14309/crj.0000000000000462
_version_ 1783588922754859008
author Strobel, Thomas
Ahmed, Waseem
De la Sancha, Carlo
Bohm, Matthew
Fischer, Monika
author_facet Strobel, Thomas
Ahmed, Waseem
De la Sancha, Carlo
Bohm, Matthew
Fischer, Monika
author_sort Strobel, Thomas
collection PubMed
description Tumor necrosis factor-α (TNF-α)-inhibiting agents are a standard therapy for moderate-to-severe inflammatory bowel disease (IBD). IgA nephropathy in the setting of prolonged exposure to TNF-α inhibitors is a rare, clinically significant adverse event often overlooked by gastroenterologists but well documented in the rheumatologic literature. We present a case series of 3 patients with IBD on TNF-α inhibitors who developed biopsy-proven IgA nephropathy. Clinicians prescribing TNF-α inhibitors to patients with IBD need to be aware of this potential side effect. Therapies with alternative mechanisms of action should instead be considered.
format Online
Article
Text
id pubmed-7526714
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-75267142020-10-14 IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease Strobel, Thomas Ahmed, Waseem De la Sancha, Carlo Bohm, Matthew Fischer, Monika ACG Case Rep J Case Report Tumor necrosis factor-α (TNF-α)-inhibiting agents are a standard therapy for moderate-to-severe inflammatory bowel disease (IBD). IgA nephropathy in the setting of prolonged exposure to TNF-α inhibitors is a rare, clinically significant adverse event often overlooked by gastroenterologists but well documented in the rheumatologic literature. We present a case series of 3 patients with IBD on TNF-α inhibitors who developed biopsy-proven IgA nephropathy. Clinicians prescribing TNF-α inhibitors to patients with IBD need to be aware of this potential side effect. Therapies with alternative mechanisms of action should instead be considered. Wolters Kluwer 2020-09-29 /pmc/articles/PMC7526714/ /pubmed/33062795 http://dx.doi.org/10.14309/crj.0000000000000462 Text en © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Strobel, Thomas
Ahmed, Waseem
De la Sancha, Carlo
Bohm, Matthew
Fischer, Monika
IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title_full IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title_fullStr IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title_full_unstemmed IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title_short IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
title_sort iga nephropathy in the setting of anti-tnf-α therapy for inflammatory bowel disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526714/
https://www.ncbi.nlm.nih.gov/pubmed/33062795
http://dx.doi.org/10.14309/crj.0000000000000462
work_keys_str_mv AT strobelthomas iganephropathyinthesettingofantitnfatherapyforinflammatoryboweldisease
AT ahmedwaseem iganephropathyinthesettingofantitnfatherapyforinflammatoryboweldisease
AT delasanchacarlo iganephropathyinthesettingofantitnfatherapyforinflammatoryboweldisease
AT bohmmatthew iganephropathyinthesettingofantitnfatherapyforinflammatoryboweldisease
AT fischermonika iganephropathyinthesettingofantitnfatherapyforinflammatoryboweldisease